Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)28.19
  • Today's Change-1.66 / -5.56%
  • Shares traded63.17k
  • 1 Year change+77.41%
  • Beta0.9208
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1535894
Total Receivables, Net152.370.21
Total Inventory------
Prepaid expenses0.480.730.61
Other current assets, total0.1602.05
Total current assets1696197
Property, plant & equipment, net0.400.040.21
Goodwill, net------
Intangibles, net015--
Long term investments----0
Note receivable - long term586469
Other long term assets0.530.260.30
Total assets234140167
LIABILITIES
Accounts payable0.650.521.07
Accrued expenses2.822.950.72
Notes payable/short-term debt000
Current portion long-term debt/capital leases5.54--0
Other current liabilities, total103.3411
Total current liabilities196.8213
Total long term debt11900
Total debt12400
Deferred income tax------
Minority interest------
Other liabilities, total7.569.5512
Total liabilities1461625
SHAREHOLDERS EQUITY
Common stock0.090.090.09
Additional paid-in capital1,3121,3061,307
Retained earnings (accumulated deficit)(1223)(1182)(1165)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity89124142
Total liabilities & shareholders' equity234140167
Total common shares outstanding111111
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.